NextBio

Help
Description: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of daunorubicin. [PubChem]
Drug Type: Small Molecule; Approved; Investigational
Pharmacology: Doxorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Doxorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Doxorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.
Mechanism of Action: Doxorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Doxorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
Indication: For the treatment of Koposi's sarcome connected to AIDS.
Half Life: 55 hours
View Complete Description




Individual Studies
  • Drug-Induced Renal Tubular Toxicity

    Rattus norvegicus Rattus norvegicus | RNA Expression   RNA Expression

    These data support the publication titled "A Gene Expression Signature that Predicts the Future Onset of Drug-Induced Renal Tubular Toxicity"

    Authors: Fielden MR, Eynon BP, Natsoulis G et al.

    Organization: Iconix Pharmaceuticals 325 E Middlefield…

  • Rhabdomyosarcoma A673 cell treatments: Cytarabine, Doxorubicin and Puromycin

    Homo sapiens Homo sapiens | RNA Expression   RNA Expression

    An increasing number of cancer-associated mutations have been identified. Unfortunately, little therapy today exploits these tumor-specific genetic lesions. Often, the resulting oncoproteins have been intractable to easy manipulation with current small molecule screening approaches. To overcome this…

    Authors: Stegmaier K, Wong JS, Ross KN et al.

    Organization: Dana-Farber Cancer Institute and Childre…

View All Individual Studies

Thought leaders and organizations working on research involving adriamycin hydrochloride.

  • Xiuling Xu
  • Xiabin Jing
  • Rui Wang
  • Xuesi Chen
  • Nathalie Heylen
  • Sequus Pharmaceuticals
  • Roswell Park Cancer Institute
  • FeRx
  • Robert H. Lurie Cancer Center
  • Sun Pharma Advanced Research Company Limited
  • Marmara University
  • Institute of Biophysics
  • Université Catholique de Louvain
  • Dabur Research Foundation
  • Teikyo University

Clinical Trials | 758 trials

Help for Clinical Trials View All

Community

Help for Community
  • No NextBio users were found for “adriamycin hydrochloride”.
    Complete your user profile with your interests, if you want others to find you within the NextBio community.

  • No NextBio groups were found for “adriamycin hydrochloride”.
    Be the first to start a group and share your interests with others within the NextBio community.